Neuroimaging Co-Core
Leader Spotlight
Dr. Frank DiFilippo, Ph.D.
Tell me about yourself and how you are involved with the Cleveland Alzheimer’s Disease Research Center (CADRC).
My primary appointment is in the Cleveland Clinic Division of Nuclear Medicine, where we perform a full range of clinical nuclear medicine services. A significant portion of our studies are brain PET scans, for patient care as well as for research and clinical trials. We collaborate with the CADRC to perform amyloid PET scans to evaluate whether or not a CADRC participant has accumulated beta amyloid protein in the brain, which is a hallmark of Alzheimer's dementia.
What are your main activities and goals as they relate to brain health?
I serve as a co-director of the CADRC NeuroImaging Core, focusing on PET scans and image analysis. PET differs from other types of brain imaging (MRI, CT) in that a tiny amount of an injected drug is imaged, which reveals the biochemical status of the brain. For example, one type of PET scan reveals the local metabolism of brain cells, which can assist with planning epilepsy surgery or diagnosing frontal-temporal dementia. Other types of PET scan reveal the presence or absence of certain proteins in the brain, which assists with diagnosing and staging Alzheimer's dementia.
What is the focus of your research currently, and where do you see your work going in the next two-five years?
Much of my work in AD involves quantitative analysis of amyloid PET images, which is highly valuable for research studies. Routine clinical amyloid PET scans currently are interpreted visually as a positive or negative scan. However this current approach does not specify the level of amyloid accumulation in the brain. Developing simplified and standardized measures of amyloid accumulation for routine clinical scans can make a significant impact in patient care.
How do you see research in brain health/Alzheimer’s Disease/dementia evolving in the next 2-5 years?
The recent approval of amyloid-lowering drugs is very exciting since the clinical trials demonstrated slower progression of AD. Further clinical trials to better understand the benefits versus risk and cost of amyloid-lowering drugs will be a focus area in the near future.
Do you have any suggestion or recommendations for students or young researchers who wish to get more involved in brain health research?
Brain health research teams such as the CADRC consist of highly motivated members with diverse skills and experiences. Many fields of study can lead to a career in brain health research.
|